Community Letter: EMBARK Part 1 Topline Results

Sarepta Therapeutics announced topline results from EMBARK, a global Phase 3 pivotal study of ELEVIDYS micro-dystrophin gene therapy for Duchenne muscular dystrophy patients between the ages of 4 through 7 years.

We are disappointed that the primary endpoint was not met, but encouraged by the statistically significant results on key pre-specified secondary endpoints.

Sarepta has communicated their expectation that the FDA will consider the totality of the data that speaks to the potential benefit in some patient populations and a commitment to this therapy and serving the Duchenne community.

Read more in Sarepta’s letter to the community

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.